2025
Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.
Im G, Asgharpour A, Aby E, Stine J, Mellinger J, Luther J, Izzy M, Haque L, Lee B, Cotter T, Sherman C, Jophlin L, Goel A, Rice J, Chandna S, Lizaola-Mayo B, Chen P, Singal A, Bansal M. Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. Journal Of Clinical Gastroenterology 2025 PMID: 40549581, DOI: 10.1097/mcg.0000000000002147.Peer-Reviewed Original ResearchWeight loss medicationsGlucagon-like peptide-1Weight lossGastroenterology providersGlucagon-like peptide-1 receptor agonistsPrescribed off-label medicationsPrescribing weight loss medicationsOff-label medicationsFDA-approved medicationsLiver transplant centersOff-label prescribingMedication prescription ratesReceptor agonistsCost/insurance coveragePrescription ratesLiver diseaseSide effectsTransplant centersPeptide-1Steatotic liver diseaseObesity educationBenefit patientsPatientsResmetiromMedicationAn AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease
Ilagan-Ying Y. An AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease. Digestive Diseases And Sciences 2025, 1-4. PMID: 40512451, DOI: 10.1007/s10620-025-09144-2.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAlcohol use disorderGastroenterology fellowsOne-hour educational interventionHealth professional traineesMultidisciplinary care modelAttitudes of providersAttitudes of cliniciansLife-saving careAddiction medicine specialistsManagement of alcohol use disorderALD-related mortalityUse disorderAlcohol use disorder pharmacotherapiesTertiary academic care centerVulnerable patient populationPrimary careCare modelHealth professionalsEducational interventionMedicine providersAddiction providersProfessional traineesLiver diseaseTreatment gapTargeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease
Yang Y, Duan Y, Lang S, Fondevila M, Schöler D, Harberts A, Cabré N, Chen S, Shao Y, Vervier K, Miyamoto Y, Zhang X, Chu H, Yang L, Tan C, Eckmann L, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Stärkel P, Lawley T, Schnabl B. Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease. Cell Host & Microbe 2025, 33: 957-972.e6. PMID: 40441146, PMCID: PMC12162233, DOI: 10.1016/j.chom.2025.05.003.Peer-Reviewed Original ResearchConceptsEthanol-induced liver diseaseAlcohol-associated liver diseaseAlcohol-associated hepatitisLiver diseaseGenome of Escherichia coliE. coliMetagenomic sequencing of fecal samplesInternational cohort of patientsGenetic manipulation of bacteriaGnotobiotic mouse modelOutcomes of patientsManipulation of bacteriaCohort of patientsScavenger receptor MARCOGlobal health burdenVirulence factorsMetagenomic sequencingGut microbiotaGenetic manipulationDisease progressionMouse modelKupffer cellsKpsMBacterial spreadInternational cohortImmunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease
Shen H, Liangpunsakul S, Iwakiri Y, Szabo G, Wang H. Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease. Cellular & Molecular Immunology 2025, 1-15. PMID: 40399593, DOI: 10.1038/s41423-025-01291-w.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseTherapeutic targetLiver diseaseOptimal treatment strategyAnti-inflammatory therapyNon-parenchymal liver cellsExtra-hepatic organsImprove patient outcomesImmune cellsImmunological mechanismsInflammatory cellsImmunological pathwaysTreatment strategiesInflammatory mediatorsDisease onsetGlobal health challengePatient outcomesNervous systemInflammationAdipose tissueLiver cellsPrecision medicineClinical researchDiseaseHealth challengesFrom embedded interprofessional clinics to expanded alcohol-associated liver disease programs.
Winder G, Arab J, Goswami Banerjee A, Bryce K, Fipps D, Hussain F, Im G, Omary L, Patel A, Patel S, Rubman S, Serper M, Shenoy A, Suzuki J, Zimbrean P, Brown K, Abouljoud M, Mellinger J. From embedded interprofessional clinics to expanded alcohol-associated liver disease programs. Liver Transplantation 2025 PMID: 40359009, DOI: 10.1097/lvt.0000000000000638.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAUD careLong-term patient relationshipsCare delivery strategiesHazardous alcohol usePatient populationInterprofessional clinicPalliative carePrimary careCare elementsCare frameworkIll patient populationPatient relationshipHealthcare systemLiver transplantationHarm reductionDisease programsCareAlcohol useLiver diseaseEnhanced supportChronic liver diseaseEating disorder treatmentCollaborative modelDisorder treatmentLiver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Sakuma I, Gaspar R, Nasiri A, Dufour S, Kahn M, Zheng J, LaMoia T, Guerra M, Taki Y, Kawashima Y, Yimlamai D, Perelis M, Vatner D, Petersen K, Huttasch M, Knebel B, Kahl S, Roden M, Samuel V, Tanaka T, Shulman G. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2502978122. PMID: 40310463, PMCID: PMC12067271, DOI: 10.1073/pnas.2502978122.Peer-Reviewed Original ResearchConceptsCholine-deficient l-amino acid-defined high-fat dietBempedoic acidLiver fibrosisLiver diseaseL-amino acid-defined high-fat dietAdvanced liver diseaseCholesterol contentHSD17B13 variantsHigh-fat dietTotal liver cholesterol contentTreated miceActivate signaling pathwaysVariant rs738409Liver cholesterol contentLiver lipidsFibrotic responsePromote inflammationTherapeutic approachesSteatotic liver diseaseDietary cholesterol supplementationFibrosisHuman liver samplesI148MAntisense oligonucleotidesProgressive formThe interplay between germline and somatic variants in alpha-1 anti-trypsin deficiency liver disease
Vilarinho S. The interplay between germline and somatic variants in alpha-1 anti-trypsin deficiency liver disease. Nature Genetics 2025, 57: 775-776. PMID: 40169790, DOI: 10.1038/s41588-025-02151-z.Peer-Reviewed Original ResearchLiver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder
Cote M, Cloonan D, Li S, Razak S, Singh R, Coe T, Zimbrean P, Andrews S, Ivkovic A, Bartels S, Chadha R, Bethea E, Yeh H, Lim N, Dageforde L. Liver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder. Transplantation Direct 2025, 11: e1766. PMID: 40078821, PMCID: PMC11896101, DOI: 10.1097/txd.0000000000001766.Peer-Reviewed Original ResearchAUD careAlcohol use disorderAlcohol-associated liver diseasePost-LTLiver transplantationManagement of alcohol use disorderLiver diseaseTreatment of alcohol use disordersTreat alcohol use disorderUse disorderPost-LT treatmentPost-LT patientsMental health professionalsMedication-assisted therapyAnalysis of categorical variablesAmerican SocietyNurse coordinatorPerceived barriersHealth professionalsProvider perspectiveChi-square testPosttransplant managementUnivariate analysis of categorical variablesVolume tertilesAlcohol abstinenceTargeting Polymeric Nanoparticles to Specific Cell Populations in the Liver
Harkins L, Vilarinho S, Saltzman W. Targeting Polymeric Nanoparticles to Specific Cell Populations in the Liver. Biochemistry 2025, 64: 1685-1697. PMID: 40127248, DOI: 10.1021/acs.biochem.4c00712.Peer-Reviewed Original ResearchConceptsLiver-resident macrophagesCell-specific targetingCell-specific deliveryAccumulation of nanoparticlesSpecific cell populationsDelivery of drugsConjugation of targeting ligandsTreatment of liver diseasesResident macrophagesKupffer cellsLiver diseaseNP administrationCell populationsConjugated nanoparticlesNP designDiseased liverSpecific deliveryCellular distributionTherapeutic carriersLiverSustained releaseNP characteristicsPolymer nanoparticlesCellsDeliveryCharacterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants
Jawaid T, Elbarougy D, Lavu S, Buia G, Senum S, Olinger E, Yang H, McDonnell S, Bublitz J, Ma J, Audrézet M, Madsen C, Schauer R, Baker T, Gregory A, Orr S, Barroso-Gil M, Neatu R, Joli G, Dahl N, Kline T, Gillion V, Dahan K, Jouret F, Perrone R, Steinman T, Peters D, Gitomer B, Watnick T, Coto E, Chebib F, Hogan M, Olson J, Larson N, Ars E, Halbritter J, Demoulin N, Torres V, Sayer J, Gall E, Harris P. Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants. Journal Of The American Society Of Nephrology 2025, 36: 1056-1071. PMID: 39899384, PMCID: PMC12147961, DOI: 10.1681/asn.0000000613.Peer-Reviewed Original ResearchPathogenic variantsAutosomal dominant polycystic kidney diseaseAutosomal dominant polycystic kidney disease geneCystic kidneysKidney cystsPKD phenotypeSequence dataAutosomal dominant polycystic liver diseaseALG8ALG9Kidney phenotypeGenesDominant polycystic kidney diseaseInherited nephropathyAnalysis of individualsPathogenic changesPolycystic kidney diseasePKD1PhenotypeKidney diseaseMcbBMutationsVariantsLiver diseaseKidney failureRecent advances in the management of pediatric cholestatic liver diseases
Mysore K, Cheng K, Suri L, Fawaz R, Mavis A, Kogan‐Liberman D, Mohammad S, Taylor S. Recent advances in the management of pediatric cholestatic liver diseases. Journal Of Pediatric Gastroenterology And Nutrition 2025, 80: 549-558. PMID: 39840645, PMCID: PMC11961318, DOI: 10.1002/jpn3.12462.Peer-Reviewed Original ResearchPediatric cholestatic liver diseasesCholestatic liver diseaseIleal bile acid transporterAlagille syndromeSlow disease progressionLiver diseaseBile acid transporterMedical therapyIleal bile acid transporter inhibitorClinical trialsDisease progressionProgressive familial intrahepatic cholestasisFamilial intrahepatic cholestasisPediatric liver transplantationBile acid toxicityCurative medical therapyAcid transportImprove patient qualityIntrahepatic cholestasisBiliary atresiaSurgical managementRare conditionLiver transplantationNutritional supportUnderlying etiologyIdentifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort.
John B, Bastaich D, Mezzacappa C, Ferreira R, Hentschel A, Samos A, Mahmud N, Taddei T, Kaplan D, Serper M, Dahman B. Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. The American Journal Of Gastroenterology 2025 PMID: 39950372, DOI: 10.14309/ajg.0000000000003321.Peer-Reviewed Original ResearchElectronic health recordsCardiometabolic risk factorsAlcohol useChart reviewRetrospective study of participantsStudy of participantsLiver diseaseSteatotic liver diseaseIncreased alcohol intakeEligible veteransICD-9/10 codesHealth recordsNational cohortAlcohol intakeEvidence of hepatic steatosisEpidemiological studiesNatural language processing algorithmsRisk factorsStudy cohortOutcome studiesVeteransCohortClinical entityRetrospective studyMetabolic dysfunctionThe evolving role of liver biopsy: Current applications and future prospects
Gopal P, Hu X, Robert M, Zhang X. The evolving role of liver biopsy: Current applications and future prospects. Hepatology Communications 2025, 9: e0628. PMID: 39774070, PMCID: PMC11717517, DOI: 10.1097/hc9.0000000000000628.Peer-Reviewed Original ResearchChapter 30 Wilson disease⊛
To U, Schilsky M. Chapter 30 Wilson disease⊛. 2025, 841-859. DOI: 10.1016/b978-0-443-26711-6.00030-5.Peer-Reviewed Original ResearchWilson's diseaseAutosomal recessive disorderATP7B proteinNegative copper balanceDiverse phenotypesATP7B geneUnexplained liver diseaseLong-term survivalCopper transportBiochemical testsGenetic testingRecessive disorderMetabolic correctionLiver transplantationMedical historyHepatic symptomsLiver diseaseATP7BCopper excretionNeurological assessmentDietary restrictionIncreased excretionCopper balancePsychiatric symptomsExcretionCirrhosis and Truly Elective Major Surgery
Jakab S, Oprea A. Cirrhosis and Truly Elective Major Surgery. 2025, 249-258. DOI: 10.1093/med/9780190902001.003.0021.Peer-Reviewed Original ResearchPrevalence of chronic liver diseasePerioperative management of patientsPreoperative risk evaluationPresence of cirrhosisType of surgeryComplications of cirrhosisManagement of patientsEfficacy of therapyChronic liver diseaseLiver synthetic dysfunctionSynthetic dysfunctionOverall prognosisPostoperative complicationsDiagnosing cirrhosisPortal hypertensionLiver transplantationPerioperative managementPatient comorbiditiesSurgical proceduresCirrhosisLiver diseasePatientsSurgical teamScoring systemSurgery
2024
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
Vutien P, Barnard Giustini A, Kim N, Moon A, Hsu C, Mezzacappa C, Borgerding J, Johnson K, VoPham T, Berry K, Beste L, Kaplan D, Taddei T, Ioannou G. Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death. Hepatology 2024 PMID: 39689352, DOI: 10.1097/hep.0000000000001183.Peer-Reviewed Original ResearchClinically significant portal hypertensionRisk of deathHepatic decompensationLiver stiffnessChronic liver diseasePlatelet countStratify risk of deathLiver diseaseRisk of hepatic decompensationMedian follow-upRisk of adverse outcomesSignificant portal hypertensionAssociated with risk of adverse outcomesRisk of decompensationAssociated with riskPortal hypertensionStratify riskFollow-upDecompensationAdverse outcomesCACLDPlatelet measuresPatientsPlateletDeathValidation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis
Mezzacappa C, Ochoa-Allemant P, Serper M, Taddei T, John B, Kaplan D, Mahmud N. Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis. Clinical Gastroenterology And Hepatology 2024 PMID: 39689774, PMCID: PMC12167392, DOI: 10.1016/j.cgh.2024.10.035.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseCardiometabolic risk factorsAlcohol use disorderSteatotic liver diseaseLiver diseaseLow high-density lipoproteinChild-Turcotte-Pugh classIncidence rateIncident hepatocellular carcinomaIncreased alcohol intakeAlcohol useClinically relevant definitionAll-cause mortalityHigher hazard of mortalityNational cohort of veteransUnited States cohortCohort of veteransAcute cardiac eventsHigh-density lipoproteinHazard of mortalityHazardous alcohol useAlcohol intakeCardiac eventsAlcohol exposureHepatocellular carcinomaNon-alcohol-related cirrhosis leads to higher 6-week mortality after acute variceal bleeding than alcohol-related cirrhosis
Wong Y, Buckholz A, Sim A, Teng M, Wong R, Curry M, De Roza M, Baffy G, Teoh X, Chak E, Rustagi T, Chang J, Wong G, Tandon P, Garcia-Tsao G, Abraldes J, Mohanty A, Fortune B. Non-alcohol-related cirrhosis leads to higher 6-week mortality after acute variceal bleeding than alcohol-related cirrhosis. Clinical Gastroenterology And Hepatology 2024 PMID: 39675401, DOI: 10.1016/j.cgh.2024.10.022.Peer-Reviewed Original ResearchAcute variceal bleedingALD cirrhosisVariceal bleedingPrognostic scoreCirrhosis etiologyPrediction of 6-week mortalityAcute variceal bleeding patientsNon-alcohol-related cirrhosisSeverity of liver diseaseEtiology of liver cirrhosisPropensity-score matching analysisMultivariate logistic regressionMulti-center cohortAVB patientsOverall cohortRisk stratificationLiver cirrhosisPatient populationCirrhosisLiver diseasePatientsAggregate cohortCohortMatching analysisEtiologyAcute Kidney Injury in Patients with Cirrhosis and Chronic Kidney Disease: Results from the HRS-HARMONY Consortium
St. Hillien S, Robinson J, Ouyang T, Patidar K, Belcher J, Cullaro G, Regner K, Chung R, Ufere N, Velez J, Neyra J, Asrani S, Wadei H, Teixeira J, Saly D, Levitsky J, Orman E, Sawinski D, Dageforde L, Allegretti A, Consortium H. Acute Kidney Injury in Patients with Cirrhosis and Chronic Kidney Disease: Results from the HRS-HARMONY Consortium. Clinical Gastroenterology And Hepatology 2024 PMID: 39675402, PMCID: PMC12163100, DOI: 10.1016/j.cgh.2024.10.023.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseLiver function parametersKidney diseaseKidney injuryAssociated with lower 90-day mortalityRates of intensive care unit admissionLiver diseaseAlcohol-associated liver diseaseIntensive care unit admissionMELD-Na scoreRenal replacement therapyShort-term outcomesFunction parametersComparison of outcomesPeak creatinineAdmission creatinineTransplant listing statusReplacement therapyUnit admissionPrimary outcomeCirrhosisMetabolic dysfunctionHospitalized patientsPatientsDepression and anxiety management in cirrhosis
Zimbrean P, Jakab S. Depression and anxiety management in cirrhosis. Hepatology Communications 2024, 9: e0600. PMID: 39670879, PMCID: PMC11637748, DOI: 10.1097/hc9.0000000000000600.Peer-Reviewed Original ResearchConceptsAnxiety disordersAnxiety symptomsPrevalence of generalized anxiety disorderDiagnosis of depressionPrevalence of depressionGeneral populationAnxietyScreening instrumentAnxiety managementTreatment interventionsDepressionPsychotherapyDisordersHealth-related quality of lifeLiver diseaseIntegrated care approachSymptomsHealth-related qualitySevere symptomsPharmacological agentsStand-alone therapyQuality of lifeCare approachAntidepressantsDose adjustment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply